Trials / Completed
CompletedNCT00220285
Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma
A Phase II Open-label Study of SH L 749 in Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphomas
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 20 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the antitumor effect and safety of the product for relapsed or refractory indolent B-cell non-Hodgkin's lymphomas.
Detailed description
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zevalin (SH L 749 , BAY86-5128) | 0,3mCi/kg |
| DRUG | Zevalin (SH L 749 , BAY86-5128) | 0,4mCi/kg |
Timeline
- Start date
- 2004-08-01
- Completion
- 2005-10-01
- First posted
- 2005-09-22
- Last updated
- 2014-12-30
Locations
9 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00220285. Inclusion in this directory is not an endorsement.